301201.SZ
诚达药业
SZSE · C 制造业 · CN
CNY 34.43
−3.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 458.3M | 406.4M | 333.1M | 414.3M | 411.5M |
| Cost of Revenue | 273.0M | 226.9M | 190.5M | 236.6M | 213.9M |
| Gross Profit | 185.3M | 179.5M | 142.6M | 177.7M | 197.5M |
| Operating Expenses | |||||
| R&D Expense | 42.2M | 40.2M | 93.7M | 27.5M | 19.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 115.8M | 123.5M | 104.0M | 88.4M | 88.3M |
| Selling & Marketing Expense | 5.0M | 4.6M | 4.6M | 3.2M | 5.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 171.2M | 174.5M | 202.6M | 114.9M | 111.9M |
| Cost and Expenses | 444.2M | 401.4M | 393.1M | 351.5M | 325.8M |
| Operating Income (EBIT) | 3.4M | (7.8M) | (24.6M) | 107.8M | 124.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (2.4M) | (13.3M) | (27.2M) | 104.2M | 120.1M |
| Income Tax Expense | 1.2M | (1.3M) | 456.1K | 13.1M | 13.6M |
| Bottom Line | |||||
| Net Income | (3.5M) | (11.9M) | (28.1M) | 91.0M | 106.5M |
| Earnings from Cont. Ops | (3.6M) | (12.0M) | (27.6M) | 91.1M | 106.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.5M) | (11.9M) | (28.1M) | 91.0M | 106.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.02) | (CN¥0.08) | (CN¥0.18) | CN¥0.59 | CN¥0.70 |
| Diluted EPS | (CN¥0.02) | (CN¥0.08) | (CN¥0.18) | CN¥0.59 | CN¥0.70 |
| Revenue Per Share | CN¥3.02 | CN¥2.68 | CN¥2.19 | CN¥2.68 | CN¥2.72 |
| Shares | |||||
| Basic Shares Outstanding | 151.6M | 151.5M | 152.0M | 154.7M | 151.5M |
| Diluted Shares Outstanding | 151.6M | 151.5M | 152.0M | 154.7M | 151.5M |
| Profitability Metrics | |||||
| EBITDA | — | 83.2M | 36.8M | 157.4M | 163.8M |
| D&A | — | 91.0M | 61.4M | 49.6M | 39.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026